[{"id":"c5069877-91bb-4251-94b9-54a5d23f9ae6","acronym":"LuMIERE","url":"https://clinicaltrials.gov/study/NCT04939610","created_at":"2023-10-21T07:12:22.742Z","updated_at":"2025-02-25T14:40:52.491Z","phase":"Phase 1/2","brief_title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","source_id_and_acronym":"NCT04939610 - LuMIERE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lutetium Lu 177 rofapitide tetraxetan (AAA614)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-14"},{"id":"36b25a6e-d1bc-4c39-aec7-9e1f51d0310f","acronym":"ZOLAR","url":"https://clinicaltrials.gov/study/NCT06537596","created_at":"2025-02-26T09:09:12.436Z","updated_at":"2025-02-26T09:09:12.436Z","phase":"Phase 1","brief_title":"89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT06537596 - ZOLAR","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","biomarkers":" PDGFRA","pipe":" | ","alterations":" FOLR1 expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lartruvo (olaratumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-12-19"},{"id":"172cf19e-4d47-4409-b143-492fc8df438e","acronym":"GPC3","url":"https://clinicaltrials.gov/study/NCT06726161","created_at":"2025-02-26T10:02:26.236Z","updated_at":"2025-02-26T10:02:26.236Z","phase":"Phase 1","brief_title":"Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC","source_id_and_acronym":"NCT06726161 - GPC3","lead_sponsor":"RayzeBio, Inc.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-12-10"},{"id":"470be808-bc58-41ba-9198-bd615bd2748f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04711135","created_at":"2021-02-11T16:55:42.049Z","updated_at":"2024-07-02T16:34:25.979Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","source_id_and_acronym":"NCT04711135","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 05/07/2029","study_completion_date":" 05/07/2029","last_update_posted":"2024-06-14"},{"id":"8958a804-5b40-4f07-97d2-e49b0ff21eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946305","created_at":"2021-06-30T17:54:27.285Z","updated_at":"2024-07-02T16:34:25.830Z","phase":"","brief_title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","source_id_and_acronym":"NCT04946305","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 07/08/2024","primary_completion_date":" 07/08/2024","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-06-14"},{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"9236ed5b-4e48-4482-beb7-c4a2d4ec1f1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05844332","created_at":"2023-05-06T15:04:24.810Z","updated_at":"2024-07-02T16:34:27.152Z","phase":"","brief_title":"LUTATHERA Injection General Use Result Survey","source_id_and_acronym":"NCT05844332","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"c6eb5752-3b02-4b81-89d4-72c52d5a889a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04090398","created_at":"2021-01-18T20:01:06.898Z","updated_at":"2024-07-02T16:34:58.839Z","phase":"Phase 2","brief_title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","source_id_and_acronym":"NCT04090398","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"3860705e-302a-47ca-86d2-2608fd1b0f73","acronym":"","url":"https://clinicaltrials.gov/study/NCT05247905","created_at":"2022-02-21T14:52:59.210Z","updated_at":"2024-07-02T16:35:01.279Z","phase":"Phase 2","brief_title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT05247905","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 10/01/2033","study_completion_date":" 10/01/2033","last_update_posted":"2024-05-23"},{"id":"9b675762-36d2-4b01-a1bb-64cbf3e1132c","acronym":"COMRADE","url":"https://clinicaltrials.gov/study/NCT03317392","created_at":"2021-01-18T16:22:57.486Z","updated_at":"2024-07-02T16:35:02.836Z","phase":"Phase 1/2","brief_title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","source_id_and_acronym":"NCT03317392 - COMRADE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HRD • CD4","pipe":" | ","alterations":" HRD","tags":["HRD • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Suspended","enrollment":" Enrollment 133","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-17"},{"id":"eeaa26ec-8cb6-416b-942f-7678bd303580","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674722","created_at":"2021-01-19T20:45:33.091Z","updated_at":"2024-07-02T16:35:02.828Z","phase":"Phase 1","brief_title":"HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody","source_id_and_acronym":"NCT04674722","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-17"},{"id":"9a8bbdf2-e4b9-4ba0-a574-823381bdf9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610891","created_at":"2022-11-09T13:56:43.468Z","updated_at":"2024-07-02T16:35:03.279Z","phase":"Phase 1","brief_title":"Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG","source_id_and_acronym":"NCT05610891","lead_sponsor":"Cellectar Biosciences, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iopofosine I-131 (CLR 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-16"},{"id":"0a7abb08-ccb1-4e69-80bd-9e92b2a533e2","acronym":"NETTER-2","url":"https://clinicaltrials.gov/study/NCT03972488","created_at":"2021-02-11T16:53:55.907Z","updated_at":"2024-07-02T16:35:03.576Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","source_id_and_acronym":"NCT03972488 - NETTER-2","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 10/29/2027","study_completion_date":" 10/29/2027","last_update_posted":"2024-05-15"},{"id":"3dd674e6-b496-4d73-a6b8-026abbece6f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05142696","created_at":"2021-12-02T15:53:46.962Z","updated_at":"2024-07-02T16:35:06.048Z","phase":"Phase 1/2","brief_title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","source_id_and_acronym":"NCT05142696","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 05/05/2025","primary_completion_date":" 05/05/2025","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2024-05-03"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"694735df-ac85-49ba-93fc-bc6caa6ca10b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868174","created_at":"2023-05-22T16:05:29.186Z","updated_at":"2025-02-25T16:18:49.188Z","phase":"Phase 1","brief_title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","source_id_and_acronym":"NCT05868174","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"79338594-273d-494e-87f7-273064c69e88","acronym":"NeoRay","url":"https://clinicaltrials.gov/study/NCT03872778","created_at":"2021-07-05T17:20:58.247Z","updated_at":"2024-07-02T16:35:07.550Z","phase":"Phase 1/2","brief_title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake","source_id_and_acronym":"NCT03872778 - NeoRay","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" HER-2 • BRCA1 • BRCA2 • CDK4","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 11/24/2025","primary_completion_date":" 11/24/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-25"},{"id":"90bc3653-4e66-4df1-bfe9-4abee846b758","acronym":"iPRRT","url":"https://clinicaltrials.gov/study/NCT05583708","created_at":"2022-10-18T14:57:03.428Z","updated_at":"2024-07-02T16:35:09.073Z","phase":"Phase 2","brief_title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","source_id_and_acronym":"NCT05583708 - iPRRT","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-17"},{"id":"3a3871a3-373b-4120-a2fd-01f883ff6944","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066437","created_at":"2023-10-04T15:10:45.245Z","updated_at":"2024-07-02T16:35:12.192Z","phase":"Phase 1/2","brief_title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","source_id_and_acronym":"NCT06066437","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-01"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"483965a6-ed6b-4cce-b166-abbe6a657118","acronym":"","url":"https://clinicaltrials.gov/study/NCT05706129","created_at":"2023-05-15T15:04:33.169Z","updated_at":"2024-07-02T16:35:12.345Z","phase":"Phase 1/2","brief_title":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05706129","lead_sponsor":"Debiopharm International SA","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ITM-91"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-29"},{"id":"fa4ac16f-1835-4662-8af1-7fcab76575bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06016855","created_at":"2023-08-30T14:08:43.881Z","updated_at":"2024-07-02T16:35:12.390Z","phase":"Phase 4","brief_title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT06016855","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2024-03-28"},{"id":"48a0919b-3b83-483a-ac34-75efef034744","acronym":"","url":"https://clinicaltrials.gov/study/NCT01476839","created_at":"2021-01-18T06:09:44.020Z","updated_at":"2024-07-02T16:35:14.031Z","phase":"Phase 1","brief_title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","source_id_and_acronym":"NCT01476839","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/09/2012","start_date":" 11/09/2012","primary_txt":" Primary completion: 07/24/2021","primary_completion_date":" 07/24/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"ba959a30-fc13-41fa-bfe2-ed5b6c5cbb41","acronym":"","url":"https://clinicaltrials.gov/study/NCT02342782","created_at":"2021-01-18T11:08:11.471Z","updated_at":"2024-07-02T16:35:14.106Z","phase":"Phase 1","brief_title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02342782","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • CD34","pipe":"","alterations":" ","tags":["ALK • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • etoposide oral • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"}]